This patient is expected to be the final patient in the second dosage cohort of the trialSAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the seco ...

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune diseaseKYV-101 is a fully human anti-CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseasesEMERYVILLE, Calif., June 20, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from auto ...

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Co ...

PONTE VEDRA BEACH, Fla. and PARSIPPANY, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- AVIS, one of the world's best known car rental brands, has today announced a multi-year extension of its partnership as the Official Rental Car Company of the PGA TOUR, PGA TOUR Champions and Korn Ferry Tour. The agreement, through 2028, will continue to provide rental vehicles for players, caddies, employees and fans at PGA TOUR-sanctioned events worldwide. AVIS has been an Official Marketing Partner and the preferred rental ca ...

Dublin, June 17, 2024 (GLOBE NEWSWIRE) -- The "Avis Budget Group (Avis) - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.The report provides comprehensive information and insights into Avis' tech activities, including its digital transformation strategies and innovation programs. Avis offers car sharing as well as car and truck rental services to customers across the world. The company conducts its operations under several brand names, including Avis, ...

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient administration was allowed and found to be feasible Currently no FDA-approved CAR-T treatments for WM Data presented at the European Hematology Association 2024 Hybrid Congress WORCESTER, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Mustang Bi ...

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral presentation includes updat ...

Thicha Satapitanon/iStock via Getty Images Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been able to advance a few CAR-T products in its pipeline. The reason why I believe that it is good to focus on this biotech next is because it is gearing up to report results from two early-stage studies, which could possibly boost shareholder value. The first candidate of which is known as cema-cel [formerly ALLO-501A] that is being advanced for the treatment of patients with relapsed/refractory chronic lymphocyti ...

Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseasesOptimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption Kyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritisEMERYVILLE, Calif., June 10, 2024 /PRNewswire/ -- Kyv ...

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its ...